IL6 and COVID-19: Gut microbiota associated with blood proteomic biomarkers has been identified in patients with COVID-19 (severe and non-severe), in order to predict COVID-19 progression to clinically severe phase, which correlated with inflammatory biomarkers such as IL-6, IL-1β, TNF-α, and high-sensitivity C-reactive protein (hsCRP) (105).